Shilpa Medicare Limited — Investor Meet, 18-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Shilpa Medicare achieved its highest ever Q1 EBITDA of INR98 crores (+18% YoY) on INR328 crores revenue (+9% YoY), driven by strong API and Biologics segments. Gross margins improved to 76%. The Board proposed a 1:1 bonus issue for increased liquidity.

The company is progressing on monetization of assets. Key highlights include India approval for Nor-Ursodeoxycholic acid (a new chemical entity) with an October launch planned via partners. API business expanded capacities and advanced NCE programs. Biologics saw significant growth from new CDMO deals and licensing, with major NBE and biosimilar programs (Nivolumab, Albumin) entering human studies next year. Management expressed confidence in sustainable, long-term growth through differentiated products and partnerships.